Substantial Equivalence Explained: What FDA Actually Looks For

The 510(k) pathway exists because Congress recognized that requiring clinical trials for every medical device improvement would paralyze innovation. Substantial equivalence is the legal shortcut — if your device is at least as safe and effective as something already on the market, it can follow the predicate to market without the full PMA process.

But "substantial equivalence" is a term of art with a specific regulatory definition. Understanding what FDA reviewers actually evaluate — and what they don't — is essential for a submission that clears on first review.

The statutory definition

Under 21 USC 360c(i)(1)(A), a device is substantially equivalent to a predicate if it:

1. Has the same intended use as the predicate, and
2. Has the same technological characteristics as the predicate, or
3. Has different technological characteristics and the information submitted demonstrates that the device is at least as safe and effective as the predicate, and does not raise different questions of safety and effectiveness

Both conditions must be satisfied. Intended use must always match. Technology can differ — but only if the difference doesn't introduce new risks FDA hasn't previously evaluated for this device type.

Intended use: what it means and doesn't mean

Intended use is the medical purpose your device is marketed for — what condition it treats or diagnoses, in which patient population, in what clinical setting. It's determined by your labeling, not your engineering.

Common intended use mistakes:

• Scope expansion — claiming a broader population or indication than the predicate supports without additional data
• Mismatched setting — predicate is for professional use only; device claims home use without addressing the safety implications
• Pediatric use — adult predicate with pediatric claims requires additional data even if the device is otherwise identical
• OTC vs prescription — these are different intended uses regardless of device similarity

Technological characteristics: the comparison FDA makes

Once FDA determines your intended use matches the predicate, it evaluates technological characteristics — the physical and chemical properties, materials, design, energy source, software, and other features that determine how the device achieves its intended use.

If your technology differs, FDA asks a two-part question:

1. Do the technological differences raise different questions of safety or effectiveness?
2. If yes, do the performance data show the device is at least as safe and effective as the predicate?

What "raises new questions" actually means

FDA reviewers use prior cleared 510(k)s, guidance documents, and their panel's technical expertise to determine whether a technological difference raises new questions.

A new material in a wound contact device raises new questions about biocompatibility — ISO 10993 testing will be expected. A new algorithm in a diagnostic device raises new questions about analytical performance — clinical validation data will be expected. A new energy delivery mechanism in a therapeutic device raises new questions about safety margins — bench and potentially clinical data will be expected.

The way to know whether your technological differences raise new questions is to look at how FDA has treated similar differences in prior clearances. If multiple cleared 510(k)s with comparable differences included biocompatibility data, you should include it too.

The split predicate strategy

FDA allows applicants to use more than one predicate — a strategy called "split predicate." You might use one predicate to establish intended use and a different predicate to establish technological characteristics. This is legitimate and FDA-accepted when no single predicate satisfies both prongs, but requires careful documentation and a coherent argument.

When FDA issues a Not Substantially Equivalent (NSE) determination

NSE doesn't mean your device can't reach market — it means the 510(k) pathway is closed for that submission. After an NSE, you can refile with a different predicate or additional data, request De Novo classification, pursue PMA, or appeal through FDA's dispute resolution process.

Building the argument before you write

The substantial equivalence argument should be built before you write the 510(k), not during. That means identifying the right predicate, documenting every technological difference, determining which differences raise new questions, and building a test plan that generates the necessary data before submission.

Applicants who treat predicate selection as a paperwork exercise face exactly the delays and NSE determinations that a more rigorous upfront analysis would have prevented.